GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
GSK says Nucala is the only drug in the new interleukin-5 inhibitor class to be approved in Europe in a once-monthly, self-administered format, adding that studies show 96% of patients prefer self ...
4don MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
UPDATED: Friday, Jan. 3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a ...
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector device in India.
Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive ... Mepolizumab (SB240563, Bosatria, Nucala, Xinkelai) is an anti-interleukin-5 (IL-5) recombinant ...
(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...
Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,359. ...
Hundreds of truckloads of food, fuel and other supplies have arrived in Gaza each day since the cease-fire took effect. But the need is vast after 15 months of war. By Vivian Yee and Bilal ...
Jan. 24, 2025 — We're nearly one month into 2025, but if you're struggling to hold onto your New Year's resolution, stay strong, as new research shows that forming a healthy habit can take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback